News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
Avance Biosciences Launches NGS Center of Excellence in Houston
Avance Biosciences has launched a state-of-the-art NGS Center of Excellence in Houston to support biologics and cell and gene therapy development. The facility offers advanced sequencing technologies, GMP- and CLIA-compliant testing, and expert bioinformatics, providing comprehensive support from early research through clinical trials and regulatory submissions...
Join Avance at the BioProcessing Summit – August 18-21, 2025
Avance Biosciences™ is proud to announce its participation in the Bioprocessing Summit 2025 in Boston, MA. Visit Booth #516 to learn how our GLP- and GMP-compliant analytical services support the development and manufacturing of biologics, cell and gene therapies, and advanced biotherapeutics...
Avance is growing to better support biopharmaceutical drug development and manufacturing
Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities...
Ensuring Data Integrity and 21 CFR Part 11 Compliance in NGS Workflows
Avance delivers end-to-end NGS workflow compliance with a robust framework for data integrity, pipeline validation, and audit readiness—tailored for regulated environments...
Groundbreaking Personalized Gene Therapy Saves Infant with Rare, Incurable Disease
An NIH-supported team has delivered the first personalized CRISPR-based gene therapy to an infant with CPS1 deficiency, offering new hope for rare disease treatment. The customized approach shows early success and may pave the way for future individualized therapies...
FDA Accelerates AI Integration to Transform Drug Review Processes
The FDA is embracing AI to streamline drug reviews, aiming for full implementation by June 2025. Following a successful pilot, this move could fast-track therapy approvals and reduce administrative tasks for scientists...